Future randomized prospective studies should address these gaps and exploring predictive biomarkers (e.g., PD-L1, tumor mutational burden and hematological test indicators) to evaluate their potential prognostic value in LA-NPC combination therapy based on PD-1 inhibitors. This evidence concerns the gene CD274 and neoplasm.